TTP LabTech acquires licensing for RAP technology

TTP LabTech has been granted a licence for the application of Inverness Medical Switzerland GmbH’s Resonant Acoustic Profiling (RAP) technology incorporated in the RAPid 4 instrument in the areas of drug discovery and life sciences.

In a separate deal TTP LabTech has acquired the design, manufacturing and marketing rights to the RAPid 4 instrument.

According to the company, RAP enables concentration measurement and analysis of the binding events between specific molecules in complex samples – something which very few technologies offer life scientists to such a high quality.

Dr Philip Blenkinsop, managing director of TTP LabTech, said: "We are tremendously excited by the opportunities that this deal presents us with.

"RAP technology is highly complementary to our current Acumen range of fluorescence-based assay platforms and will enable our customers, both existing and new, to perform label-free interaction analysis on their development drugs."

Mr Blenkinsop added that the company intends to use the technology to address new markets such as biotherapeutic development and protein expression analysis.

Earlier this year, TTP LabTech entered into a collaboration with Cell Signalling Technology to develop and co-market antibodies and assay solutions.